RNA as performance-enhancers for dendritic cells

Abstract

Importance of the field: Although studies have demonstrated that antigen-loaded dendritic cells (DC) elicit antigen-specific immune responses, the clinical benefit from DC-based cancer immunotherapy remains low. RNA, in the form of mRNA, has not only been used as a source of antigen but more recently as a way to stimulate DC to produce immunostimulatory molecules. As siRNA it has allowed researchers to modify DC to produce a favorable cytokine profile or to present antigen that may generate the desired immune response.

Areas covered in this review: When loading DC with RNA that encodes immunostimulatory protein, rather than a source of antigen, optimal translation and efficient transfection into DC are critical. Studies addressing these issues and the functional consequences of modulating DC function are reviewed.

What the reader will gain: RNA can be used to load DC with antigen and to encode proteins that will enhance the immune response. Co-transfection with multiple mRNAs or mRNA plus siRNA can significantly improve vaccine efficacy.

Take home message: One conclusion from Phase I clinical trials with DC loaded with tumor antigen is that tumor-specific induction of immune responses is not sufficient to destroy pre-established tumors. The advantage of transfection with mRNA is the ability to load DC with antigen-encoding mRNA and immunostimulatory protein-encoding mRNA to achieve the desired clinical response.

Keywords::

• antibody-encoding RNA
• cancer immunotherapy
• mRNA and siRNA transfection
• RNA-transfected dendritic cells

Notes

This box summarises key points contained in the article.